Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 1
1995 2
1996 1
1997 1
2000 1
2003 1
2008 2
2009 1
2010 1
2011 1
2013 2
2014 1
2015 2
2016 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A. Grossmann KF, et al. Among authors: kovacsovics bankowski m. Cancer Discov. 2022 Mar 1;12(3):644-653. doi: 10.1158/2159-8290.CD-21-1141. Cancer Discov. 2022. PMID: 34764195 Clinical Trial.
Signaling through OX40 enhances antitumor immunity.
Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA. Jensen SM, et al. Among authors: kovacsovics bankowski m. Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Semin Oncol. 2010. PMID: 21074068 Free PMC article. Review.
Science gone translational: the OX40 agonist story.
Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Weinberg AD, et al. Among authors: kovacsovics bankowski m. Immunol Rev. 2011 Nov;244(1):218-31. doi: 10.1111/j.1600-065X.2011.01069.x. Immunol Rev. 2011. PMID: 22017441 Free PMC article. Review.
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE, Kovacsovics-Bankowski M, Weinberg AD. Moran AE, et al. Among authors: kovacsovics bankowski m. Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14. Curr Opin Immunol. 2013. PMID: 23414607 Free PMC article. Review.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD. Curti BD, et al. Among authors: kovacsovics bankowski m. Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31. Cancer Res. 2013. PMID: 24177180 Free PMC article. Clinical Trial.
Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities.
Kovacsovics-Bankowski M, Chisholm L, Vercellini J, Tucker CG, Montler R, Haley D, Newell P, Ma J, Tseng P, Wolf R, Vetto JT, Hammill C, Hansen P, Weinberg AD. Kovacsovics-Bankowski M, et al. J Immunother Cancer. 2014 Nov 18;2(1):38. doi: 10.1186/s40425-014-0038-9. eCollection 2014. J Immunother Cancer. 2014. PMID: 25436113 Free PMC article.
19 results